Cat Spire (cat allergy T-cell vaccine)fails in phase III study.- Circassia Pharma.
Circassia Pharmaceuticals plc announced top-line results from its investigational cat allergy immunotherapy phase III study. In the study, both treatment regimens and placebo greatly, and equally, reduced subjects� combined allergy symptom and rescue medication use score from baseline. As a result of the very marked placebo effect the treatment did not meet the study�s primary endpoint. The treatment was well tolerated with a highly favourable safety profile.
Circassia will now review the study�s full dataset to understand the detailed results and assess whether any other confounding factors affected the outcome, as well as the implications for its allergy portfolio. In the meantime, the Company will stop the recently initiated registration study of its grass allergy treatment and the preparatory work for a dose-ranging study of its ragweed allergy therapy. The phase IIb study of Circassia�s house dust mite allergy product is well advanced and the Company will assess the implications associated with continuing the trial. Circassia�s birch allergy product is nearing completion of a phase II study, which will therefore continue.
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.